@misc{10481/97164,
year = {2021},
month = {6},
url = {https://hdl.handle.net/10481/97164},
abstract = {Visceral obesity is an important component of metabolic syndrome, a cluster of diseases
that also includes diabetes and insulin resistance. A combination of these metabolic
disorders damages liver function, which manifests as non-alcoholic fatty liver disease
(NAFLD). NAFLD is a common cause of abnormal liver function, and numerous studies
have established the enormously deleterious role of hepatic steatosis in ischemiareperfusion
(I/R) injury that inevitably occurs in both liver resection and transplantation.
Thus, steatotic livers exhibit a higher frequency of post-surgical complications after
hepatectomy, and using liver grafts from donors with NAFLD is associated with an
increased risk of post-surgical morbidity and mortality in the recipient. Diabetes, another
MetS-related metabolic disorder, also worsens hepatic I/R injury, and similar to NAFLD,
diabetes is associated with a poor prognosis after liver surgery. Due to the large increase
in the prevalence of MetS, NAFLD, and diabetes, their association is frequent in the
population and therefore, in patients requiring liver resection and in potential liver graft
donors. This scenario requires advancement in therapies to improve postoperative
results in patients suffering from metabolic diseases and undergoing liver surgery; and
in this sense, the bases for designing therapeutic strategies are in-depth knowledge
about the molecular signaling pathways underlying the effects of MetS-related diseases
and I/R injury on liver tissue. A common denominator in all these diseases is autophagy.
In fact, in the context of obesity, autophagy is profoundly diminished in hepatocytes
and alters mitochondrial functions in the liver. In insulin resistance conditions, there is
a suppression of autophagy in the liver, which is associated with the accumulation of
lipids, being this is a risk factor for NAFLD. Also, oxidative stress occurring in hepatic
I/R injury promotes autophagy. The present review aims to shed some light on the role of autophagy in livers undergoing surgery and also suffering from metabolic diseases,
which may lead to the discovery of effective therapeutic targets that could be translated
from laboratory to clinical practice, to improve postoperative results of liver surgeries
when performed in the presence of one or more metabolic diseases.},
organization = {Ministerio de Ciencia,
Innovación y Universidades (Project Grant RTI2018-095114-
B-I00) Madrid, Spain},
organization = {European Union (Fondos FEDER,
“una manera de hacer Europa”)},
organization = {CERCA Program/Generalitat
de Catalunya},
organization = {the Secretaria d’ Universitats I Recerca del
Departament d’ Economia I Coneixement (Project Grant
2017_SGR_551) Barcelona, Spain, by the COST action Programs
CA17103 (DARTER), CA17112 (PRO-EURO-DILI-NET),
CA17121 (COMULIS), and CA17126 (TUMIEE)},
organization = {Consejo Nacional de Ciencia y Tecnología (CONACYT), Fondo
Sectorial de Investigación para la Educación (Project grant
257743), México},
organization = {FCT (Fundació Catalana de trasplantament), Spain},
publisher = {Frontiers Media},
keywords = {autophagy},
keywords = {metabolic syndrome},
keywords = {ischemia-reperfusion},
title = {New Insights Into the Role of Autophagy in Liver Surgery in the Setting of Metabolic Syndrome and Related Diseases},
doi = {10.3389/fcell.2021.670273},
author = {Álvarez Mercado, Ana Isabel and Rojano-Alfonso, Carlos and Micó-Carnero, Marc and Caballeria Casals, Albert and Peralta, Carmen and Casillas-Ramírez, Araní},
}